GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor

被引:6
|
作者
Eroglu, Evren Caglar [1 ]
Gulec, Umran Kucukgoz [2 ]
Vardar, Mehmet Ali [2 ]
Paydas, Semra [3 ]
机构
[1] Alata Hort Res Inst, Mersin, Turkey
[2] Cukurova Univ, Med Fac, Dept Gynecol Oncol, Adana, Turkey
[3] Cukurova Univ, Med Fac, Dept Oncol, Adana, Turkey
关键词
metabolomics; biomarker; ovarian cancer; benign tumor; healthy control; GC-MS; OPLS-DA; BIOMARKER DISCOVERY; MASS-SPECTROMETRY; PROSTATE-CANCER; METABOLOMICS; DIAGNOSIS; URINE; SERUM; IDENTIFICATION; PLASMA;
D O I
10.1177/14690667221098520
中图分类号
O64 [物理化学(理论化学)、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号
070203 ; 070304 ; 081704 ; 1406 ;
摘要
The aim of this study is to identify urinary metabolomic profile of benign and malign ovarian tumors patients. Samples were analyzed using gas chromatography-mass spectrometry (GC-MS) and metabolomic tools to define biomarkers that cause differentiation between groups. 7 metabolites were found to be different in patients with ovarian cancer (OC) and benign tumors (BT). R2Y and Q2 values were found to be 0.670 and 0.459, respectively. L-tyrosine, glycine, stearic acid, turanose and L-threonine metabolites were defined as prominent biomarkers. The sensitivity of the model was calculated as 90.72% and the specificity as 82.09%. In the pathway analysis, glutathione metabolism, aminoacyl-tRNA biosynthesis, glycine serine and threonine metabolic pathway, primary bile acid biosynthesis pathways were found to be important. According to the t-test, 29 metabolites were found to be significant in urine samples of OC patients and healthy controls (HC). R2Y and Q2 values were found to be 0.8170 and 0.749, respectively. These results showed that the model has high compatibility and predictive power. Benzoic acid, L-threonine, L-pyroglutamic acid, creatinine and 3,4-dihydroxyphenylacetic acid metabolites were determined as prominent biomarkers. The sensitivity of the model was calculated as 93.81% and the specificity as 98.59%. Glycine serine and threonine metabolic pathway, glutathione metabolism and aminoacyl-tRNA biosynthesis pathways were determined important in OC patients and HC. The R2Y, Q2, sensitivity and specificity values in the urine samples of BT patients and HC were found to be 0.869, 0.794, 91.75, 97.01% and 97.18%, respectively. L-threonine, L-pyroglutamic acid, benzoic acid, creatinine and pentadecanol metabolites were determined as prominent biomarkers. Valine, leucine and isoleucine biosynthesis and aminoacyl-tRNA biosynthesis were significant. In this study, thanks to the untargeted metabolomic approach and chemometric methods, every group was differentiated from the others and prominent biomarkers were determined.
引用
收藏
页码:12 / 24
页数:13
相关论文
共 50 条
  • [1] Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors
    Buas, Matthew F.
    Gu, Haiwei
    Djukovic, Danijel
    Zhu, Jiangjiang
    Drescher, Charles W.
    Urban, Nicole
    Raftery, Daniel
    Li, Christopher I.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (01) : 138 - 144
  • [2] Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
    Dey, Puja
    Nakayama, Kentaro
    Razia, Sultana
    Ishikawa, Masako
    Ishibashi, Tomoka
    Yamashita, Hitomi
    Kanno, Kosuke
    Sato, Seiya
    Kiyono, Tohru
    Kyo, Satoru
    CANCERS, 2022, 14 (06)
  • [3] Different expression of S100A11 in normal ovarian epithelium, serous benign/borderline tumor, and low-grade serous ovarian carcinoma
    Li, Yanli
    Liu, Suqing
    Hu, Chengcheng
    Xu, Wei
    Wu, Sufang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (07): : 7420 - 7427
  • [4] CORRELATION BETWEEN OVARIAN TUMOR SIZE AND CLINICAL FEATURES AND PROGNOSIS OF OVARIAN SEROUS CARCINOMA
    Yang, L.
    Guo, H. G.
    Chiao, J. Q.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 482 - 482
  • [5] Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor
    Chougule, Abhijit
    Garg, Rashi
    Dey, Pranab
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (01) : 162 - +
  • [6] Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma
    Jazaeri, AA
    Lu, K
    Schmandt, R
    Harris, CP
    Rao, PH
    Sotiriou, C
    Chandramouli, GVR
    Gershenson, DM
    Liu, ET
    MOLECULAR CARCINOGENESIS, 2003, 36 (02) : 53 - 59
  • [7] Patterns of tumor evolution in high grade serous ovarian carcinoma
    Verhaak, Roel G. W.
    Chang, Kyle
    Kim, Hoon
    Carter, Scott L.
    Schultz, Nikolaus
    Zhao, Fengmei
    Shen, Hui
    Laird, Peter
    Sinah, Rileen
    Muzny, Donna
    Reid, Jeff
    Nu, Jiangong
    Drummond, Jennifer
    Getz, Gad
    Levine, Douglas A.
    Wheeler, David A.
    CANCER RESEARCH, 2012, 72
  • [8] Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
    Sally M. Hunter
    Genevieve V. Dall
    Maria A. Doyle
    Richard Lupat
    Jason Li
    Prue Allan
    Simone M. Rowley
    David Bowtell
    Ian G. Campbell
    Kylie L. Gorringe
    BMC Research Notes, 13
  • [9] Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
    Hunter, Sally M.
    Dall, Genevieve V.
    Doyle, Maria A.
    Lupat, Richard
    Li, Jason
    Allan, Prue
    Rowley, Simone M.
    Bowtell, David
    Campbell, Ian G.
    Gorringe, Kylie L.
    BMC RESEARCH NOTES, 2020, 13 (01)
  • [10] Classification of serous ovarian carcinoma based on immunogenomic profiling
    Chen, Peigen
    Zhang, Yu
    Liang, Changyan
    Yang, Yuebo
    Li, Yunhui
    Wan, Jing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 91